| Document Date: 2013-06-03 04:06:57
Open Document File Size: 585,29 KBShare Result on Facebook
City Lausanne / / Company Novartis / Debiopharm Group / / Country Switzerland / Japan / United States / Brazil / / / Facility Yale University / / / IndustryTerm biopharmaceutical / treatment of advanced prostate cancer / clinical scale-cGMP manufacturing facilities / manufacturing / pharmaceutical / treatment of colorectal cancer / / MedicalCondition advanced prostate cancer / metabolic diseases / colorectal cancer / endometriosis / diseases / infectious diseases / female infertility / neurodegenerative disorders / central precocious puberty / / Organization Haute Ecole / Ecole Polytechnique Fédérale de Lausanne / EPFL / FDA / Yale University / / / Position chair / / Product Eloxatin / Trelstar / / Technology Drug delivery / / URL www.debiopharm.com / /
SocialTag |
W E TR AN S FO R M YO U R M O LE CU LE I NTO A R EG I STE R E D D R UG Debiopharm’s core activities consist in: